Gt Biopharma, INC 10-Q quarterly reports

GT Biopharma's Q2 2026 report highlights significant operating losses and cash burn, raising substantial doubt about its ability to continue as a going concern, despite progress in its clinical pipeline.

GT Biopharma reports a wider net loss for Q1 2026 compared to the prior year, driven by increased selling, general, and administrative expenses, while research and development costs decreased.

GT Biopharma, Inc. has filed an amended quarterly report for Q2 2025, restating financials due to material errors in classifying Greenshoe Rights as a liability, significantly increasing net loss and accumulated deficit.

GT Biopharma, Inc. has filed an amended quarterly report for Q3 2025 to correct material errors related to Greenshoe Rights liability classification, while reporting a wider net loss for the nine months ended September 30, 2025.

GT Biopharma reported a significantly reduced net loss and a return to positive stockholders' equity for the nine months ended September 30, 2025, while advancing its TriKE immuno-oncology pipeline.

GT Biopharma reports a narrowed net loss for Q2 2025, highlights progress in clinical trials, and raises concerns over liquidity challenges.

GT Biopharma reports a net loss of $776,000 for Q1 2025, highlighting advancements in clinical trials and cost-cutting measures.

GT Biopharma reported its financial results for the third quarter of 2024, highlighting progress in its TriKE platform development and clinical trial preparations.

GT Biopharma reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and financial position.

GT Biopharma reported a net loss of $2.27 million for the first quarter of 2024, while progressing its TriKE platform and preparing for clinical trials.